• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Barr Eliav was granted 9,321 shares, increasing direct ownership by 22% to 51,189 units (SEC Form 4)

    6/23/25 4:09:58 PM ET
    $VCYT
    Medical Specialities
    Health Care
    Get the next $VCYT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Barr Eliav

    (Last) (First) (Middle)
    6000 SHORELINE COURT, SUITE 300

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    VERACYTE, INC. [ VCYT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/18/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/18/2025 A(1) 9,321 A $0 51,189 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Restricted stock units awarded on June 18, 2025 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.
    Remarks:
    /s/ Jonathan Wygant as attorney-in-fact 06/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VCYT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VCYT

    DatePrice TargetRatingAnalyst
    3/20/2025$45.00Buy
    Craig Hallum
    12/5/2024$38.00 → $37.00Buy → Neutral
    Goldman
    11/15/2024$50.00Outperform
    Wolfe Research
    10/16/2024$43.00Buy
    UBS
    10/10/2024$40.00Buy
    Guggenheim
    2/23/2024$30.00 → $33.00Buy
    Needham
    1/18/2023Outperform → Mkt Perform
    Raymond James
    1/5/2023$33.00Sector Outperform
    Scotiabank
    More analyst ratings

    $VCYT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Veracyte Inc.

    SCHEDULE 13G/A - VERACYTE, INC. (0001384101) (Subject)

    8/12/25 10:34:25 AM ET
    $VCYT
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Veracyte Inc.

    10-Q - VERACYTE, INC. (0001384101) (Filer)

    8/7/25 4:41:08 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - VERACYTE, INC. (0001384101) (Filer)

    8/6/25 4:08:41 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eastham Karin was granted 9,321 shares, increasing direct ownership by 67% to 23,228 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    6/23/25 4:10:37 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Director Holstein Jens was granted 9,321 shares, increasing direct ownership by 33% to 37,199 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    6/23/25 4:10:27 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Director Jones Evan/ Fa was granted 9,321 shares, increasing direct ownership by 27% to 43,664 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    6/23/25 4:10:17 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veracyte Announces Second Quarter 2025 Financial Results

    Grew total revenue to $130.2 million and testing revenue to $122.3 million, representing increases of 14% year-over-year Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. "Testing growth continues to exceed our expectations, driven by Decipher which achieved its thirteenth consecutive quarter of over 25% year-over-year volume growth," said Marc Stapley, Veracyte's chief executive officer. "This strong result, combined with Afirma volume meeting our expectations and the resolution of the French subsidiary proceedings, has positioned us for in

    8/6/25 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Set to Join S&P SmallCap 600

    NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE:TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners LLC will acquire Triumph Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 29, 2025 S&P SmallCap 600 Addition Veracyte VCYT Health Care July 29, 2025 S&P SmallCap 600 Deletion Triumph Group TGI Industrials For more information about S&P Dow Jones Indices,

    7/24/25 5:58:00 PM ET
    $SPGI
    $TGI
    $VCYT
    Finance: Consumer Services
    Finance
    Aerospace
    Industrials

    Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter of 2025 after the close of market on Wednesday, August 6, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/5gqvvmtt. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte

    7/17/25 5:30:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Veracyte with a new price target

    Craig Hallum initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00

    3/20/25 7:42:48 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte downgraded by Goldman with a new price target

    Goldman downgraded Veracyte from Buy to Neutral and set a new price target of $37.00 from $38.00 previously

    12/5/24 8:24:30 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Wolfe Research initiated coverage on Veracyte with a new price target

    Wolfe Research initiated coverage of Veracyte with a rating of Outperform and set a new price target of $50.00

    11/15/24 8:25:09 AM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Leadership Updates

    Live Leadership Updates

    View All

    Veracyte Set to Join S&P SmallCap 600

    NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE:TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners LLC will acquire Triumph Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 29, 2025 S&P SmallCap 600 Addition Veracyte VCYT Health Care July 29, 2025 S&P SmallCap 600 Deletion Triumph Group TGI Industrials For more information about S&P Dow Jones Indices,

    7/24/25 5:58:00 PM ET
    $SPGI
    $TGI
    $VCYT
    Finance: Consumer Services
    Finance
    Aerospace
    Industrials

    Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac

    9/4/24 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

    Veracyte, Inc. (NASDAQ:VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927846710/en/Veracyte Names Phillip G. Febbo, M.D., a

    9/27/23 9:00:00 AM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Veracyte Inc.

    SC 13G - VERACYTE, INC. (0001384101) (Subject)

    11/12/24 9:30:49 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

    SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

    11/8/24 10:41:07 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

    SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

    10/2/24 2:12:30 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Financials

    Live finance-specific insights

    View All

    Veracyte Announces Second Quarter 2025 Financial Results

    Grew total revenue to $130.2 million and testing revenue to $122.3 million, representing increases of 14% year-over-year Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. "Testing growth continues to exceed our expectations, driven by Decipher which achieved its thirteenth consecutive quarter of over 25% year-over-year volume growth," said Marc Stapley, Veracyte's chief executive officer. "This strong result, combined with Afirma volume meeting our expectations and the resolution of the French subsidiary proceedings, has positioned us for in

    8/6/25 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter of 2025 after the close of market on Wednesday, August 6, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/5gqvvmtt. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte

    7/17/25 5:30:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Announces First Quarter 2025 Financial Results

    Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand," said Marc Stapley, Veracyte's chief executive officer. "With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in a

    5/7/25 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care